Becton, Dickinson & Company appoints new Managing Director for India & South Asia

New Delhi: BD (Becton, Dickinson and Company), a leading global medical technology company has appointed Pavan Mocherla as the new Managing Director for its India and South Asia operations. The medical technology giant aims to improve medical discovery, diagnostics and the delivery of care.

Mr Pavan will be relocating to India from the US to be at the helm of affairs in the country. With more than 25 years of experience across various industries, Pavan has held multiple positions and managed several projects in both emerging and developed markets. A strong believer in living the BD values of continuously improving and innovating and doing it right, he has been with BD for 14+years in business and strategic roles.

In his last assignment in BD for Strategic Innovation, he was instrumental in setting up an Innovation System to accelerate growth opportunities for the markets of China and South East Asia. In his current role, Pavan will be driving patient safety initiatives like Antimicrobial Resistance (AMR), Healthcare associated infections (HAI) reduction etc. and spearhead projects to improve access to technology in the global health space (HIV, TB etc.) through engagement with stakeholders across Government and multilateral agencies.

Prior to BD, he was associated with organisations like Whirlpool, ONIDA and NIIT Ltd. Pavan completed his MBA in Marketing from Central University, Pondicherry and Bachelors in Science from Osmania University, Hyderabad.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For details, please visit bd.com

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US